Marion Merrell Dow: Difference between revisions
Americasroof (talk | contribs) No edit summary |
Americasroof (talk | contribs) |
||
| Line 32: | Line 32: | ||
In the 1980s it marketed [[Sivadone]] (a burn cream), [[Ditropan]] (treatment for [[bladder infections]]), [[Nito-Bid]] ([[chest pain]] treatment), [[Ard]] and [[Bac-T-Screen]] (helped identify bacteria), [[Culturette]] (used to to identify Group A [[streptococci]]) and ToxiLab, a drug detection system used to detect [[drug abuse]]. |
In the 1980s it marketed [[Sivadone]] (a burn cream), [[Ditropan]] (treatment for [[bladder infections]]), [[Nito-Bid]] ([[chest pain]] treatment), [[Ard]] and [[Bac-T-Screen]] (helped identify bacteria), [[Culturette]] (used to to identify Group A [[streptococci]]) and ToxiLab, a drug detection system used to detect [[drug abuse]]. |
||
===Marion Merrell Dow=== |
===Marion Merrell Dow=== |
||
In 1989 Merrell Dow, a subdivision of [[Dow Chemical]] acquired 67 percent interest and the company was renamed Marion Merrell Dow. Among the products Merrell Dow brought that would be shortly marked were Seldane, Lorelco, Nicorette and Cepacol. The merger was considered a good fit because of Marion Laboratories strong sales force and Merrell Dow's strong research and develop capabilities. |
In 1989 '''Merrell Dow Pharmaceuticals''', a subdivision of [[Dow Chemical]] acquired 67 percent interest and the company was renamed Marion Merrell Dow. Among the products Merrell Dow brought that would be shortly marked were Seldane, Lorelco, Nicorette and Cepacol. The merger was considered a good fit because of Marion Laboratories strong sales force and Merrell Dow's strong research and develop capabilities. |
||
The new company traded on the [[New York Stock Exchange]] under the [[ticker symbol]] "MKC." |
The new company traded on the [[New York Stock Exchange]] under the [[ticker symbol]] "MKC." |
||
===Hoechst Marion Roussel=== |
===Hoechst Marion Roussel=== |
||
In 1995 [[Hoechst AG]] of Germany announced plans to buy Dow's increased 71 percent share for $25.75 a share or $7.1 Billion -- a profit of between $4 and $5 billion for Dow. Hoeschst also bought the other outstanding shares.<ref>[http://findarticles.com/p/articles/mi_qa3653/is_199505/ai_n8732298 Hoechst agrees to acquire Marion Merrell Dow - Corporate Growth Weekly - May 15, 1995]</ref> |
In 1995 [[Hoechst AG]] of Germany announced plans to buy Dow's increased 71 percent share for $25.75 a share or $7.1 Billion -- a profit of between $4 and $5 billion for Dow. Hoeschst also bought the other outstanding shares.<ref>[http://findarticles.com/p/articles/mi_qa3653/is_199505/ai_n8732298 Hoechst agrees to acquire Marion Merrell Dow - Corporate Growth Weekly - May 15, 1995]</ref> |
||
Revision as of 17:35, 24 August 2008
| Industry | Pharmaceutical |
|---|---|
| Founded | 1950 (Marion Laboratories) 1989 (Marion Merrell Dow) |
| Defunct | 1996 |
| Fate | Acquired by Hoechst AG |
| Successor | Hoechst Marion Roussel |
| Headquarters | Kansas City, Missouri |
Marion Merrell Dow and its predecessor Marion Laboratories was a pharmecuteical company based in Kansas City, Missouri from 1950 until 1996.
The company specialized in bringing to market drugs that had been discovered but unmarketed by other companies including Cardizem (which slowed calcium build up), Carafate (an ulcer treatment), Gaviscon (an antacid), Seldane (antihistamine), Nicorette (anti-smoking gum) and Cepacol mouthwash.
The company operating out of its headquarters at 9300 Ward Parkway was a springboard for its founder Ewing Marion Kauffman to start the Kansas City Royals baseball team.
History
Marion Laboratories
Kauffman, a former pharmaceutical salesman in Decatur, Illinois started the company in the basement of his Kansas City home by selling calcium supplements made from crushed oyster shells which he made in his home and starting with $4,000 in capital. Kaufmann would say later he used his middle name for the company to avoid the impression that it was a one-person operation.
The company quickly took off. As Kauffman expanded he offered his employees share options and profit sharing.
Rather researching products, the company adopted a policy of buy products discovered by other companies and reformulating them for market.
In 1964 it formally incorporated at Marion Laboratories, Inc.
In the 1980s it marketed Sivadone (a burn cream), Ditropan (treatment for bladder infections), Nito-Bid (chest pain treatment), Ard and Bac-T-Screen (helped identify bacteria), Culturette (used to to identify Group A streptococci) and ToxiLab, a drug detection system used to detect drug abuse.
Marion Merrell Dow
In 1989 Merrell Dow Pharmaceuticals, a subdivision of Dow Chemical acquired 67 percent interest and the company was renamed Marion Merrell Dow. Among the products Merrell Dow brought that would be shortly marked were Seldane, Lorelco, Nicorette and Cepacol. The merger was considered a good fit because of Marion Laboratories strong sales force and Merrell Dow's strong research and develop capabilities.
The new company traded on the New York Stock Exchange under the ticker symbol "MKC."
Hoechst Marion Roussel
In 1995 Hoechst AG of Germany announced plans to buy Dow's increased 71 percent share for $25.75 a share or $7.1 Billion -- a profit of between $4 and $5 billion for Dow. Hoeschst also bought the other outstanding shares.[1]
Hoescht's new pharaceutical company became Hoechst Marion Roussel. Hoescht in turn would become Sanofi-Aventis.
Supreme Court Cases
In the U.S., Merrell Dow Pharmaceuticals was a named party in at least two major United States Supreme Court cases:
- Merrell Dow Pharmaceuticals Inc. v. Thompson, 478 U.S. 804 (1986), involving original jurisdiction
- Daubert v. Merrell Dow Pharmaceuticals 509 U.S. 579 (1993), applied the rules governing expert testimony established by the Federal Rules of Evidence to the admission of scientific evidence at trials conducted in federal courts
References
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |